We read with great interest the review article by Russo et al. titled [1]. The authors provided a comprehensive and timely overview of the "four pillars" of heart failure therapy—RAAS inhibitors, beta-blockers, MRAs, and SGLT2 inhibitors—specifically focusing on their renal implications. We commend the authors for clearly articulating the paradigm shift brought by SGLT2 inhibitors, highlighting their unique ability to reverse the trajectory of renal decline while providing robust cardiovascular protection.
